Best Oncology Companies in Singapore
The 43 best Oncology companies in Singapore in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Tessa.
- Pharma 50 Deep Dive: Oncology leads with $110B in sales; GLP-1s contin
- Oncology Market Is Encouraged to Reach USD 646.33 Billion by 2032
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Singapore
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Tessa Developer of next-generation cell therapies for cancer | $256M | 50 mo ago | Deadpooled | — | 2011 | — | — | — |
| 2 | Mirxes Developer of miRNA based test for the detection of cancer | $207M | 37 mo ago | Public | Zhou Lihan Co-Founder & CEO | 2014 | WordPressApple iCloud MailMicrosoft 365+36 | — | 1 launch · 1 partnership |
| 3 | Hummingbird Bioscience Developer of antibody drugs for cancer treatment | $150M | 63 mo ago | Series C | Jerome Boyd-Kirkup Co-Founder & CSO | 2015 | WordPressMySQLPHP+20 | 151 patents Antibody-based cancer therapeutics targeting B7‑H3, HER3, Trop2 antigens | — |
| 4 | Medisix Therapeutics Developer of CAR-T therapies to treat cancer and autoimmune diseases | $63M | 64 mo ago | Series B | Dario Campana Founder | 2017 | — | 21 patents CAR‑T cell engineering with CD3 blockade and multi‑protein expression control | — |
| 5 | ImmunoSCAPE Immune profiling services through their proprietary platform | $39M | 47 mo ago | Series B | — | 2016 | — | — | — |
| 6 | AUM Biosciences Developer of small molecules for cancer treatment | $28M | 58 mo ago | Series A | Vishal Doshi Founder& CEO | 2018 | WordPressMySQLPHP+16 | — | — |
| 7 | Alternative Bio Developer of novel therapeutics to treat intractable cancers | $15M | 44 mo ago | Seed | Fei Lan Co-Founder | — | — | — | — |
| 8 | Axcynsis Therapeutics Developer of immunotherapies for cancer treatment | $15M | 51 mo ago | Seed | Zou Bin Founder & CEO | 2022 | — | 12 patents Antibody‑drug conjugates targeting HCLDN6 and ALPP/ALPPL2 tumor antigens with trabectedin/lurbinectedin payloads | — |
| 9 | Sunbird Bio Developer of blood-based diagnostic tests for neurological disorders | $14M | 22 mo ago | Series B | Carine Lim Co-Founder | 2020 | WixSentryBootstrap+11 | — | — |
| 10 | Endofotonics Raman spectroscopy-based endoscopic system | $8M | 75 mo ago | Series B | Cheng Kum Co-Founder & CEO | 2014 | — | — | — |
| 11 | SCG Developer of immunotherapies for pathogenic infections and cancers | $8M | 40 mo ago | Series C | — | 2017 | Microsoft ASP.NETTengineModernizr+3 | — | — |
| 12 | DotBio Provider of antibody-based therapies | $6M | 36 mo ago | Seed | Ignacio Asial Founder & CEO | 2018 | — | — | 1 award |
| 13 | Albatroz Therapeutics Developer of therapeutic antibodies for cancer and arthritis | $3M | 39 mo ago | Seed | Frederic Bard Co-Founder & CEO | 2020 | — | 8 patents Calnexin-targeted antibodies for IBD treatment and diagnostic assays. | — |
| 14 | CytoMed Therapeutics Developer of immunotherapeutics for treating cancer | $1M | 80 mo ago | Public | — | 2018 | — | — | — |
| 15 | Avatamed Developer of drugs for cancer treatments | $1M | 72 mo ago | Seed | Yun Kuk Founder & CEO | 2019 | — | — | — |
| 16 | StratifiCare Provider of in-vitro diagnostics solutions for infectious diseases | $729K | 58 mo ago | Seed | Jin Chua Co-Founder & CEO | 2015 | — | — | — |
Top 12 Oncology companies in Singapore
#1
Series B · Singapore · founded 2020 · 12 employees$14Mraised▾
Developer of blood-based diagnostic tests for neurological disorders. The company’s technology detects proteins associated with neurological disorders. These tests support diagnosis and treatment of diseases, such as Alzheimer's, Parkinson's, and ALS. The technology aims to provide researchers and clinicians with diagnostic information for differential diagnoses.
- Oct 2024Series B$14M
#2
Public · Singapore, Singapore · founded 2014 · 400 employees$207Mraised▾
Developer of miRNA-based test for the detection of cancer. The company's core technology is a highly specific RT-PCR primer that imposes a conformational restriction on miRNA for efficient binding to mature, but not precursor miRNAs, coupled with optimized RT-PCR reagents. These primers confer high specificity, sensitivity, and enhanced signal-to-noise ratio in amplification reactions. The company manufactures miRNA detection and quantification kits for research and is developing miRNA-based liquid biopsy kits for gastric cancer, lung cancer, and breast cancer detection.
- Jul 2023Series D$50M
- Oct 2021Series C$87M
- Jul 2021Series C$77M
- Aug 2019Series A$40M
#3
Deadpooled · Singapore, Singapore · founded 2011 · 183 employees$256Mraised▾
Developer of next-generation cell therapies for cancer. The therapies include TT11 CD30-CAR-Ts for classical Hodgkin lymphoma and CD30+ non-Hodgkin lymphoma, TT11X Allogeneic CD30-CAR EBVSTs for CD30+ lymphoma, and TT16 HER2-CAR-Ts + CAdVEC for HER2+ cancer. These products are for the treatment of hematologic malignancies and solid tumors.
- Jun 2022Series A$126M
- Apr 2018Series A$50M
- Dec 2017Series A$80M
#4
Series C · Singapore, Singapore · founded 2015 · 112 employees$150Mraised▾
Developer of antibody drugs for cancer treatment. It is involved in developing antibodies by using systems immunology and computational structural biology technology. The company is using platform technology for the design and development of therapeutic antibodies. The pipelined products are HMBD-001 is a monoclonal antibody, HMBD-002 is an anti-vista monoclonal antibody for cancer-treating.
- May 2021Series C$125M
- May 2020Series B$6M
- Dec 2019Series B$19M
- Jul 2019Series A—
#5
Series B · Singapore, Singapore · founded 2016 · 43 employees$39Mraised▾
immunoSCAPE offers specialized services for biomarker and target identification through its unique high-dimensional immune profiling platform. Founded as a spin-off from the lab of Dr Evan Newell at Singapore Immunology Network, A*STAR, the company uses its expertise in immunology and mass cytometry to measure alterations of immune cells and T-cell specificity in specific and helps in optimizing the early phase R&D pipeline for oncology and infectious diseases.Their proprietary technology leverages the power of mass cytometry (Cytometry by Time of Flight), T-Cell antigen discovery and cell profiling techniques and related data analysis tools. Their services for immunotherapy development include surrogate marker ID, disease status and progression determination and prediction, discovery of novel targets and biomarkers, and efficacy assessment in preclinical and clinical stages.
- Sep 2022Series B$14M
- Apr 2021Series B$14M
- Aug 2020Series A$11M
- Jan 2020Seed—
#6
Seed · Singapore, Singapore · founded 2018 · 12 employees$5.6Mraised▾
DotBio provides antibody-based therapies. The company is building a bank of mono-specific DotBody modules, which can be combined rapidly into bi- and multi-specific formats. The company's therapeutic antibody technology platform that is based on a humanized VH domain antibody optimized for autonomous folding, stability, high expression levels, concentrability, and low aggregation.
- Aug 2023Seed$5.6M
#7
Seed · Singapore, Singapore$15Mraised▾
Developer of novel therapeutics to treat intractable cancers
#8
Series C · Singapore, Singapore · founded 2017 · 12 employees$8.1Mraised▾
Developer of immunotherapies for pathogenic infections and cancers. The company targets the most common cancer-causing infections helicobacter pylori, human papillomavirus, and hepatitis B, and develops a broad and unique pipeline of T cell therapies, antibodies, and therapeutic vaccines against infections and to prevent and cure its associated cancers.
- Apr 2023Series C$8.1M
#9
Series B · Singapore, Singapore · founded 2017 · 23 employees$62.9Mraised▾
Developer of CAR-T therapies to treat cancer and autoimmune diseases. The company leverages an array of proprietary technologies PEBL that improve and expand T-cell function. The company develops a pipeline of programs for hematologic malignancies and autoimmune diseases.
- Apr 2021Series B$22.5M
- Oct 2019Series A$20.4M
- May 2018Series A$20M
#10
Series A · Singapore, Singapore · founded 2018 · 18 employees$28.5Mraised▾
Developer of small molecules for cancer treatment. The company is focusing on the development of niche busters targeting highly selective oncology therapeutics. The product pipeline includes AUM001 and AUM302 for hematological malignancies.
- Oct 2021Series A$27M
- Dec 2018Seed$1.5M
#11
Seed · Singapore, Singapore · founded 2022 · 23 employees$15Mraised▾
Developer of immunotherapies for cancer treatment. It offers antibody X conjugate therapeutics based on proprietary discovery platforms which include AT 01, AT 03, and AT 04 for solid tumors. It integrates three core technologies for antibody drug conjugate development suhc as AxcynMAB, AxcynCYS, and AxcynDOT.
- May 2022Seed$15M
#12
Seed · Singapore, Singapore · founded 2020$3Mraised▾
Developer of therapeutic antibodies for cancer and arthritis. It offers therapeutics for extracellular matrix remodeling disorders which target Calnexin, a solid tumor surface protein essential for disulfide bond breakage and also found in synovial fibroblasts involved in cartilage degradation.
- May 2023Seed$3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Oncology & Cancer Therapeutics is moving in Singapore
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 727 Singapore-affiliated papers.
- Ministry of Education247
- National University of Singapore183
- Agency for Science, Technology and Research130
- Nanyang Technological University101
- Institute of Molecular and Cell Biology66
- Tumor microenvironment7→173
- Immunotherapy2→123
- Immune system1→107
- Cancer research3→108
- Cancer immunotherapy2→72
- Tumor microenvironment2→141
- Immunotherapy2→101
- Cancer research5→94
- Cancer immunotherapy1→41
- Metastasis2→22
- Tumor microenvironment1→33
- Immunotherapy1→29
- Immune system1→27
- Cancer immunotherapy1→13
Where oncology is researched across Singapore
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.